Table 1. Clinical features of 319 participants in the CRC-SCA at enrollment.
| SCA1 | SCA2 | SCA3 | SCA6 | |
|---|---|---|---|---|
| Demographic feature | ||||
| Sample size, n | 53 | 69 | 129 | 68 |
| Mean age, y (SD) | 50.3 (13.0) | 50.9 (13.5) | 51.4 (12.3) | 65.5 (10.8) |
| Sex, male/female | 24/29 | 29/40 | 62/67 | 30/38 |
| White race, % | 90.6 | 73.9 | 54.2 | 91.2 |
| Mean age of onset (SD) | 40.2 (11.7) | 36.4 (11.9) N = 68 | 38.9 (11.9) N = 127 | 52.3 (10.4) |
| Mean disease duration (SD) | 8.8 (6.9) | 13.6 (8.3) N = 68 | 11.5 (7.8) N =128 | 11.7 (10.5) |
| Median repeats (range) | 46 (37-59) N = 52 | 39 (23-49) N = 64 | 71 (60-79) N =119 | 22 (22-27) N = 65 |
| Functional state | ||||
| SARA score (SD) | 14.4 (8.2) | 17.1 (7.4) | 15.1 (8.9) N 5128 | 14.1 (7.4) |
| UHDRS-IV score (SD) | 18.7 (6.3) | 18.2 (6.3) N = 68 | 17.2 (6.9) | 18.6 (5.8) |
| PHQ-9 score (SD) | 6.1 (6.7) N = 49 | 5.3 (5.4) N = 64 | 7.3 (5.8) N = 123 | 6.5 (6.0) N = 64 |
| Medication use, n (%) | ||||
| Coenzyme Q10 | 14 (26.4) | 9 (13.0) | 31 (24.0) | 20 (29.4) |
| Statin | 8 (15.1) | 7 (10.1) | 15 (11.6) | 13 (19.1) |
| Vitamin E | 6 (11.3) | 9 (13.0) | 14 (10.9) | 11 (16.2) |
| Riluzole | 3 (5.7) | 1 (1.4) | 9 (7.0) | 2 (2.9) |
| Varenicline | 1 (1.9) | 0 (0) | 4 (3.1) | 2 (2.9) |
Sd, standard deviation.